4//SEC Filing
OLUKOTUN ADEOYE Y 4
Accession 0001209191-22-001328
CIK 0000879407other
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 9:33 PM ET
Size
9.4 KB
Accession
0001209191-22-001328
Insider Transaction Report
Form 4
OLUKOTUN ADEOYE Y
Director
Transactions
- Sale
Common Stock
2022-01-03$65.04/sh−1,916$124,617→ 5,194 total - Sale
Common Stock
2022-01-03$64.26/sh−1,890$121,451→ 7,110 total - Sale
Common Stock
2022-01-03$66.25/sh−244$16,165→ 4,950 total
Footnotes (3)
- [F1]The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.72 to $64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.74 to $65.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4
Documents
Issuer
ARROWHEAD PHARMACEUTICALS, INC.
CIK 0000879407
Entity typeother
Related Parties
1- filerCIK 0001242615
Filing Metadata
- Form type
- 4
- Filed
- Jan 3, 7:00 PM ET
- Accepted
- Jan 4, 9:33 PM ET
- Size
- 9.4 KB